It has been reported that not only new drugs but also generics have joined the competition in the market for glucagon-like peptide-1 (GLP-1)- containing treatment for diabetes and obesity. In the United States, generic versions of liraglutide, which is an active ingredient of the diabetes obesity·treatments Victoza·Saxenda that are GLP-1 receptor agonists. In addition to the development of generic versions of liraglutide, generics of dulaglutide, an active ingredient of Trulicity, are under development.

Due to the benefits of effective weight loss with GLP-1 agonists, obesity treatment usage is significantly increasing. Several GLP-1 agonists for treating obesity, including semaglutide and liraglutide, a